US 9,029,322

Application 12/663,091 · Granted May 12, 2015

Compounds for enhancing p21 expression and methods of use thereof

Estimated expiration

February 21, 2030

3y 92d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Jun 5, 2008
+ 20 years
Jun 5, 2028
PTA +626d
Feb 21, 2030
No TD
—
Final
Feb 21, 2030

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
March 22, 2010
Earliest effective filing
June 5, 2008
Issue date
May 12, 2015
PTA
+626 days
Base expiry (before PTA)
June 5, 2028

June 5, 2008 + 20 years = June 5, 2028 + 626 PTA days = February 21, 2030

  • National stage entry of application PCTUS2008007168, filed Jun 5, 2008
  • PRO60/933,366 — Provisional — not used for base term
  • PRO60/933,366 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 12/663,091 · US 9,029,322

PatentReply compiles the prosecution history behind US 9,029,322: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US9029322

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.